57718-28-2 Usage
Uses
Used in Pharmaceutical Industry:
(5-CHLORO-2-HYDROXY-PHENYL)-UREA is used as an intermediate in the synthesis of pharmaceuticals for its potential therapeutic properties and contribution to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, (5-CHLORO-2-HYDROXY-PHENYL)-UREA is employed as an intermediate in the production of agrochemicals, which are essential for enhancing crop protection and yield.
Used in Organic Synthesis:
(5-CHLORO-2-HYDROXY-PHENYL)-UREA is used as a reagent in organic synthesis, facilitating various chemical reactions and contributing to the creation of new organic compounds.
Used in Medicinal Chemistry Research:
As a research tool in medicinal chemistry, (5-CHLORO-2-HYDROXY-PHENYL)-UREA aids scientists in studying the mechanisms of action, structure-activity relationships, and potential applications of new drug candidates.
It is important to handle and use (5-CHLORO-2-HYDROXY-PHENYL)-UREA with care, adhering to proper safety precautions and procedures to ensure safe and effective applications across industries.
Check Digit Verification of cas no
The CAS Registry Mumber 57718-28-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,7,1 and 8 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 57718-28:
(7*5)+(6*7)+(5*7)+(4*1)+(3*8)+(2*2)+(1*8)=152
152 % 10 = 2
So 57718-28-2 is a valid CAS Registry Number.
57718-28-2Relevant academic research and scientific papers
N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS
-
, (2008/06/13)
The present invention relates to new antagonists of the interaction between the CCR1 Chemokine receptor and its ligands, including MIP-1α (CCL3), in particular new N-amide derivatives of 8-azabicyclo[3.2.1]oct-3-yl of formula (I).
NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES
-
Page 240, (2008/06/13)
The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Novel compounds
-
, (2008/06/13)
The invention provides compounds of general formula (I) wherein Q, R, R2, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
